Ramnath N et al. - In a trial to evaluate tolerability and activity of low-dose CPT-11 followed 24 h later by gemcitabine as second-line therapy in pts with metastatic non-small cell lung cancer (NSCLC), it was found that this regimen yielded comparable disease control rates vs other studies, but this approach was associated with higher grade 3/4 neutropenia and is not recommended for further study in metastatic NSCLC Methods
CPT-11 (60 mg/m2) was administered 24 h before gemcitabine (1000 mg/m2) on days 1, 2, 8, and 9 every 3 weeks
29 pts were evaluable for response
Results
Median follow-up was 7.4 months
Partial response (PR) was seen in 2; PR and stable disease were seen in 22 pts; median survival time was 13.8 months
Median time to progression was 4.6 months
38 pts were evaluable for toxicity; neutropenia (grade 3 or 4) was observed in 27 pts
8 pts did not receive cycle 2 of therapy owing to prolonged neutropenia
See all
